| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | 140.79% | Canaccord Genuity | $20 → $17 | Maintains | Buy |
| 10/05/2023 | 183.29% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 09/25/2023 | 169.12% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 07/13/2023 | 183.29% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 04/17/2023 | 84.14% | Raymond James | $14 → $13 | Downgrades | Strong Buy → Outperform |
| 04/03/2023 | 98.3% | Raymond James | $22 → $14 | Maintains | Strong Buy |
| 01/06/2023 | 211.61% | Raymond James | $25 → $22 | Maintains | Strong Buy |
| 10/07/2022 | 254.11% | Raymond James | $27 → $25 | Maintains | Strong Buy |
| 07/13/2022 | 282.44% | Raymond James | $32 → $27 | Maintains | Strong Buy |
| 10/15/2021 | 424.08% | Canaccord Genuity | $28 → $37 | Upgrades | Hold → Buy |
| 08/20/2021 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 07/14/2021 | 296.6% | Canaccord Genuity | $24 → $28 | Maintains | Hold |
| 07/09/2021 | 353.26% | Raymond James | $27 → $32 | Maintains | Strong Buy |
| 03/31/2021 | 239.94% | Canaccord Genuity | $18 → $24 | Maintains | Hold |
| 01/08/2021 | 239.94% | Raymond James | $18 → $24 | Maintains | Strong Buy |
| 11/25/2020 | 154.96% | Raymond James | → $18 | Upgrades | Market Perform → Strong Buy |
| 04/08/2020 | 98.3% | Canaccord Genuity | $18 → $14 | Maintains | Hold |
| 04/08/2020 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 10/04/2019 | 197.45% | Keybanc | $30 → $21 | Maintains | Overweight |
| 01/07/2019 | 225.78% | Canaccord Genuity | $20 → $23 | Maintains | Hold |
What is the target price for AngioDynamics (ANGO)?
The latest price target for AngioDynamics (NASDAQ: ANGO) was reported by Canaccord Genuity on October 5, 2023. The analyst firm set a price target for $17.00 expecting ANGO to rise to within 12 months (a possible 140.79% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AngioDynamics (ANGO)?
The latest analyst rating for AngioDynamics (NASDAQ: ANGO) was provided by Canaccord Genuity, and AngioDynamics maintained their buy rating.
When is the next analyst rating going to be posted or updated for AngioDynamics (ANGO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AngioDynamics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AngioDynamics was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
Is the Analyst Rating AngioDynamics (ANGO) correct?
While ratings are subjective and will change, the latest AngioDynamics (ANGO) rating was a maintained with a price target of $20.00 to $17.00. The current price AngioDynamics (ANGO) is trading at is $7.06, which is out of the analyst's predicted range.